This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Nefiracetam
Nefiracetam is a fat-soluble synthetic racetam developed in Japan that modulates multiple neurotransmitter systems including cholinergic, GABAergic, and glutamatergic pathways. It has been investigated for age-related cognitive decline and shows particular promise for long-term memory enhancement.
Benefits
What is Nefiracetam?
Nefiracetam (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide, also known as DM-9384) was developed by Daiichi Pharmaceutical Company in Japan as a follow-up to piracetam and aniracetam. It is structurally related to aniracetam but has a distinct pharmacological profile characterised by effects on a broader range of neurotransmitter systems.
What makes nefiracetam particularly interesting among the racetams is its ability to simultaneously modulate cholinergic, GABAergic, and glutamatergic neurotransmission. While most racetams primarily affect one or two systems, nefiracetam appears to coordinate activity across multiple pathways involved in learning and memory. This multi-target approach may explain the robust memory-enhancing effects observed in animal studies.
Nefiracetam advanced to Phase 2 clinical trials in the United States and Japan for the treatment of cognitive impairment following stroke and for Alzheimer's disease. While it showed some promise for post-stroke cognitive recovery, development was ultimately discontinued due to concerns about testicular toxicity observed in long-term animal studies at high doses.
- Cholinergic enhancement: Nefiracetam potentiates nicotinic acetylcholine receptor (nAChR) activity and enhances acetylcholine release in the hippocampus, supporting memory formation and retrieval.
- GABAergic modulation: It prolongs the opening of GABA-A receptor chloride channels without affecting the binding of GABA itself, producing a unique modulatory effect that may balance excitatory and inhibitory neurotransmission.
- Glutamatergic activity: Nefiracetam potentiates NMDA receptor currents and may enhance long-term potentiation (LTP), the synaptic strengthening process underlying memory consolidation.
- Protein kinase C activation: Activates PKC and CaM kinase II in the hippocampus, enzymes involved in synaptic plasticity and memory formation.
- Calcium channel modulation: May interact with L-type calcium channels, influencing neurotransmitter release and neuronal excitability.
- Typical dose: 100-900 mg per day, divided into 2-3 doses
- Common protocol: 150-300 mg taken 2-3 times daily
- Clinical trials: Used doses of 150-450 mg three times daily (450-1350 mg/day total)
- Fat-soluble: Take with a fat-containing meal or fat supplement for optimal absorption
- Timing: Divide doses evenly throughout the day for consistent blood levels
Nefiracetam is fat-soluble and should be taken with dietary fat. Effects on memory may become more pronounced with consistent use over days to weeks.
- Testicular toxicity: Long-term animal studies at high doses (300 mg/kg/day in dogs) showed testicular toxicity. This was a major factor in discontinuing clinical development. Lower doses in shorter-term human trials did not show this effect, but it remains a significant concern.
- Discontinued development: Nefiracetam is no longer being actively developed as a pharmaceutical, meaning safety data from large-scale trials is limited.
- Side effects: Generally well tolerated in completed clinical trials. Reported side effects include headache, nausea, dizziness, and GI discomfort.
- Regulatory status: Not approved as a pharmaceutical anywhere. Available as an unregulated research compound in most countries.
- Male reproductive concern: Males should be particularly cautious given the animal testicular toxicity data. Long-term use is not recommended.
- Pregnancy: Absolutely avoid. Insufficient safety data and concerning animal toxicology.
Natural Sources & Forms
- Synthetic compound: Nefiracetam does not occur naturally and must be synthesised
- Bulk powder: Available from specialty nootropic vendors
- Capsules: Some vendors offer pre-measured capsules
- Quality note: As with all synthetic nootropics, third-party certificates of analysis are essential for verifying purity and identity
Frequently Asked Questions
Nefiracetam is a fat-soluble synthetic racetam developed in Japan that modulates multiple neurotransmitter systems including cholinergic, GABAergic, and glutamatergic pathways. It has been investigated for age-related cognitive decline and shows particular promise for long-term memory enhancement.
The key benefits of Nefiracetam include: Anxiety & Calm, Cognitive Enhancement, Focus, Memory, Mood, Motivation.
Cholinergic enhancement: Nefiracetam potentiates nicotinic acetylcholine receptor (nAChR) activity and enhances acetylcholine release in the hippocampus, supporting memory formation and retrieval. GABAergic modulation: It prolongs the opening of GABA-A receptor chloride channels without affecting the binding of GABA itself, producing a unique modulatory effect that may balance excitatory and inhibitory neurotransmission. Glutamatergic activity: Nefiracetam potentiates NMDA receptor currents and may enhance long-term potentiation (LTP), the synaptic strengthening process underlying memory consolidation. Protein kinase C activation: Activates PKC and CaM kinase II in the hippocampus, enzymes involved in synaptic plasticity and memory formation. Calcium channel modulation: May interact with L-type calcium channels, influencing neurotransmitter release and neuronal excitability.
Typical dose: 100-900 mg per day, divided into 2-3 doses Common protocol: 150-300 mg taken 2-3 times daily Clinical trials: Used doses of 150-450 mg three times daily (450-1350 mg/day total) Fat-soluble: Take with a fat-containing meal or fat supplement for optimal absorption Timing: Divide doses evenly throughout the day for consistent blood levels Nefiracetam is fat-soluble and should be taken with dietary fat. Effects on memory may become more pronounced with consistent use over days to weeks.
Testicular toxicity: Long-term animal studies at high doses (300 mg/kg/day in dogs) showed testicular toxicity. This was a major factor in discontinuing clinical development. Lower doses in shorter-term human trials did not show this effect, but it remains a significant concern. Discontinued development: Nefiracetam is no longer being actively developed as a pharmaceutical, meaning safety data from large-scale trials is limited. Side effects: Generally well tolerated in completed clinical trials. Reported side effects include headache, nausea, dizziness, and GI discomfort. Regulatory status: Not approved as a pharmaceutical anywhere. Available as an unregulated research compound in most countries. Male reproductive concern: Males should be particularly cautious given the animal testicular toxicity data. Long-term use is not recommended. Pregnancy: Absolutely avoid. Insufficient safety data and concerning animal toxicology.
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!